Home > Products > Tumor Cell Lines > Human Tumor Cell Lines >
Daudi |
||||
|---|---|---|---|---|
| Product Name |
Daudi |
|||
| Price | Get Quote | |||
| Product Code | DAUDI; NK-10A; NK-10a; NK 10a; NK10a; N |
|||
| Cat.No |
ABC-TC0204 |
Species |
Human |
|
| Size/Quantity |
1 vial |
Biosafety Level |
1 |
|
| Shipping Info |
Dry Ice |
Storage |
Liquid Nitrogen |
|
| Description |
Why choose Daudi from AcceGen? Daudi cells from AcceGen exhibit high viability and quality, ensuring robust experimental results. They are provided in a sterile state and rigorously screened for the absence of contaminants, including bacteria, yeast, fungi, mycoplasma, HIV, HBV, and HCV. Moreover, their identity is confirmed through STR analysis, further ensuring the reliability and authenticity of these cells for research applications. |
|||
| Disease | Burkitt’s Lymphoma |
|||
| Source Organ | Blood |
|||
| Recommended Medium And Supplement | RPMI 1640 + 2mM Glutamine + 10% FBS |
|||
| Citation Guide |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID). |
|||
| Application | FOR RESEARCH USE ONLY These well-characterized Daudi B lymphoblasts have been extensively used in the study of leukemogenesis, serving as a valuable model system for understanding the intricacies of B cell biology. Their utility extends to the analysis of B cell surface antigens, enabling the exploration of antigen expression and characterization. Moreover, Daudi cells are employed in the testing of cytotoxic drugs, mutational analysis, and investigations into apoptotic mechanisms, contributing significantly to research across these pivotal areas in oncology and immunology. |
|||
| Growth Conditions | 37 ℃, 5% CO2 |
|||
| Cell Type | Lymphoblast |
|||
| Growth Mode | Suspension |
|||
| Product Type |
Human Lymphoma Cell Lines |
|||
| Product Image |
|
|||
The Daudi cell line, derived from a 16-year-old male Burkitt’s Lymphoma patient of African descent in 1967, primarily comprises B lymphoblasts and is characterized by its EBV-positive status along with the expression of mRNA for the proto-oncogene BCL2. Notably, these cells exhibit a deficiency in surface expression of HLA-ABC molecules due to the absence of beta-2-microglobulin, which is essential for the proper intracellular folding and processing of MHC class I molecules within the endoplasmic reticulum. It is advisable to employ a subculturing strategy with a split ratio ranging from 1:2 to 1:4 every 2-4 days, although initial growth of these cells may be relatively slow.
- ONLINE INQUIRY
- PRODUCT REVIEWS
Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
